7/12/2023 Monitoring note EN
Scope has completed a monitoring review for Sanofi S.A.
The periodic review has resulted in no rating action.
19/4/2023 Monitoring note EN
Updated analytical report on Sanofi S.A.
Following the recent affirmation of the Sanofi S.A. issuer rating, Scope has updated its analytical report on Sanofi S.A.
11/4/2023 Rating announcement EN
Scope affirms Sanofi’s AA/Stable issuer rating
The affirmation reflects Sanofi’s resilient operating performance and low indebtedness.
20/4/2022 Rating announcement EN
Scope affirms Sanofi’s AA issuer rating and revises the Outlook to Stable from Positive.
The rating action reflects our view of delayed deleveraging against our previous expectations.
19/5/2021 Rating announcement EN
Scope Ratings affirms Sanofi's AA issuer rating and changes the Outlook to Positive
The ratings continue to reflect Sanofi's improved positioning in growth sectors like rare diseases and immunology as well as management's credit-supportive financial policy.
9/9/2020 Rating announcement EN
Scope affirms AA/Stable issuer rating on Sanofi
The ratings reflect the company's leading position in a number of therapeutic areas as well as recent success with newly approved drugs contributing to a good credit metrics recovery in 2019, which Scope expects to continue.
19/9/2019 Rating announcement EN
Scope affirms Sanofi at AA, Stable Outlook
The rating reflects Sanofi's leading positions in vaccines, anti-diabetics and rare diseases within a credit-supportive underlying industry as well as the strong recovery for credit metrics expected by rating agency.
18/9/2018 Rating announcement EN
Scope affirms AA Sanofi rating
The rating reflects our view of Sanofi's credit metrics' recovery to levels commensurate with the ratings following their temporary deterioration following the acquisitions of Bioverativ and Ablynx in the first half of 2018.
13/3/2018 Monitoring note EN
Sanofi’s 2017 results exceeded Scope’s expectations and compensate for acquisition effects
Strong 2017 credit metrics supportive to mitigate impact from two debt-funded acquisitions in 2018
25/1/2018 Monitoring note EN
Sanofi ratings unaffected by Bioverativ acquisition
Scope believes that the recently announced USD 11.6 bn acquisition of US-based biotech company Bioverativ is not a challenge for Sanofi’s credit rating.